Mersana Therapeutics to effect 1-for-25 reverse stock split to regain Nasdaq compliance

Mersana Therapeutics, Inc.

Reverse stock split ratio set at 1-for-25; effective July 25, 2025 at 5:00 p.m. ET.
No fractional shares issued; stockholders receive cash in lieu of fractional shares.
Common stock begins trading on split-adjusted basis July 28, 2025 under ticker MRSN.
Authorized shares unchanged; proportionate adjustments made to equity awards and plans.
Split intended to bring company into compliance with Nasdaq minimum bid price requirement.

item 3.03item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.